Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(4.37)
# 395
Out of 4,650 analysts
39
Total ratings
51.28%
Success rate
21.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Reiterates: Overweight | n/a | $3.60 | - | 1 | Oct 18, 2024 | |
| VERA Vera Therapeutics | Reiterates: Overweight | $107 | $42.97 | +149.01% | 7 | Oct 3, 2024 | |
| PLRX Pliant Therapeutics | Reiterates: Overweight | n/a | $14.72 | - | 4 | Aug 8, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $19.12 | - | 4 | Aug 6, 2024 | |
| ALEC Alector | Reiterates: Overweight | n/a | $5.07 | - | 4 | Jul 29, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Overweight | n/a | $27.75 | - | 1 | Jun 27, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Overweight | n/a | $22.35 | - | 4 | Jun 18, 2024 | |
| ANNX Annexon | Reiterates: Overweight | n/a | $7.57 | - | 8 | Jun 5, 2024 | |
| RZLT Rezolute | Reiterates: Overweight | $5 | $5.68 | -11.97% | 3 | Sep 19, 2023 | |
| ABOS Acumen Pharmaceuticals | Reiterates: Overweight | $13 | $2.91 | +347.50% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $12.20 | -34.43% | 1 | Mar 20, 2023 |
Verastem
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.60
Upside: -
Vera Therapeutics
Oct 3, 2024
Reiterates: Overweight
Price Target: $107
Current: $42.97
Upside: +149.01%
Pliant Therapeutics
Aug 8, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.72
Upside: -
Arcturus Therapeutics Holdings
Aug 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.12
Upside: -
Alector
Jul 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.07
Upside: -
Dianthus Therapeutics
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $27.75
Upside: -
Jasper Therapeutics
Jun 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.35
Upside: -
Annexon
Jun 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.57
Upside: -
Rezolute
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $5.68
Upside: -11.97%
Acumen Pharmaceuticals
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $2.91
Upside: +347.50%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $12.20
Upside: -34.43%